Crossmark

Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an “outpatient” alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation

Crossref DOI link: https://doi.org/10.1038/s41409-024-02380-6

Published Online: 2024-09-09

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vo, Phuong https://orcid.org/0000-0002-0823-0244
Srinivasan, Ramaprasad

Purev, Enkhtsetseg

McDuffee, Emily

Worthy, Tatyana

Shalabi, Reem

Wood, Kristen

Wells, Brian

Reger, Robert

Stroncek, David

Geller, Nancy

Aue, Georg

Tian, Xin

Childs, Richard
License Information

Text and Data Mining valid from 2024-09-09

Version of Record valid from 2024-09-09
More Information

Article History

Received: 27 June 2024

Revised: 15 July 2024

Accepted: 24 July 2024

First Online: 9 September 2024

Competing interests

: The authors declare no competing interests.

: All participants signed written informed-consent forms. The authors have obtained informed consent for publication of the images. The study was approved by the NHLBI Institutional Review Board. All procedures were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was registered in ClinicalTrials.gov (NCT00047060).

Document is current

Any future updates will be listed below